RT Journal Article
SR Electronic
T1 Clinical utility of Corona Virus Disease-19 serum IgG, IgM, and neutralizing antibodies and inflammatory markers
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.19.21249604
DO 10.1101/2021.01.19.21249604
A1 Schaefer, Ernst J.
A1 Comite, Florence
A1 Dulipsingh, Latha
A1 Lang, Maxine
A1 Jimison, Jessica
A1 Grajower, Martin M.
A1 Lebowitz, Nathan E.
A1 Geller, Andrew S.
A1 Diffenderfer, Margaret R.
A1 He, Lihong
A1 Breton, Gary
A1 Dansinger, Michael L.
A1 Saida, Ben
A1 Yuan, Chong
YR 2021
UL http://medrxiv.org/content/early/2021/01/20/2021.01.19.21249604.abstract
AB Most deaths from severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection occur in older subjects. We assessed age effects and clinical utility of serum SARS-CoV-2 immunoglobulin G (IgG), immunoglobulin M (IgM), and neutralizing antibodies and serum inflammatory markers. Serum IgG, IgM, and neutralizing antibody levels were measured using chemiluminescence assays from Diazyme (Poway, CA), while serum interleukin-6 (IL-6), C reactive protein (CRP), and ferritin were measured with immunoassays obtained from Roche (Indianapolis, IN). In 79,005 subjects, IgG and IgM levels were positive (≥1.0 arbitrary units [AU]/mL) in 5.29% and 3.25% of subjects, respectively. In antibody positive subjects, median IgG levels were 3.93 AU/mL if <45 years of age, 10.18 AU/mL if 45-64 years of age, and 10.85 AU/mL if ≥65 years of age (p<0.0001). In SARS-CoV-2 RNA positive cases, family members and exposed subjects (n=1,111), antibody testing was found to be valuable for case finding, and persistent IgM levels were associated with chronic symptoms. In non-hospitalized and hospitalized subjects assessed for SARS-CoV-2 RNA (n=278), median IgG levels in AU/mL were 0.05 in negative subjects (n=100), 14.83 in positive outpatients (n=129), and 30.61 in positive hospitalized patients (n=49, p<0.0001). Neutralizing antibody levels correlated significantly with IgG (r=0.875; p<0.0001). Two or more of the criteria of IL-6 ≥10 pg/mL, CRP ≥10 mg/L, and/or IgM >1.0 AU/mL occurred in 97.7% of inpatients versus 1.8% of outpatients (>50-fold relative risk, C statistic 0.986, p<0.0001). Our data indicate that: 1) IgG levels are significantly higher in positive older subjects, possibly to compensate for decreased cellular immunity with aging; 2) IgG levels are important for case finding in family clusters; 3) IgG levels are significantly correlated with neutralizing antibody levels; 4) persistently elevated IgM levels are associated with chronic disease; and 5) markedly elevated IL-6, hs-CRP, and/or positive IgM accurately identify SARS-CoV-2 RNA positive subjects requiring hospitalization.Competing Interest StatementThe authors have declared no competing interest.Clinical Trialnot a clinical trialFunding StatementSupport for this research was received from Boston Heart Diagnostics, the Comite Center for Precision Medicine and Health, and Trinity Health of New England. Many of the authors are either full-time or part-time employees of the reference laboratory supporting this study (Boston Heart Diagnostics) or of the antibody kit manufacturer (Diazyme Corporation). No payments were received from any third party to influence the results of the research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All subject information was anonymized prior to data analysis, and all relevant ethical guidelines were followed. STROBE Guidelines for Observation Studies were followed for the reference laboratory dataset. IRB oversight for patient data extracted from medical records without name or identification and analyzed as anonymized data was approved by Advarra Institutional Review Board (Columbia, MD). As stated in the manuscript, the determination of the Advisory Review dated 25. September 2020 was "had the request for exempt determination been submitted prior to initiation of research activities, the research would have met the criteria for exemption from IRB review under 45 CFR 46.104(d)(4)." The study population includes a subset of previously diagnosed COVID-19 subjects enrolled in a human IRB-approved protocol at Trinity Health of New England (Hartford, CT).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe raw data from this study are available upon request to the corresponding author.